CPEB1, a histone-modified hypomethylated gene, is regulated by miR-101 and involved in cell senescence in glioma

Cell Death and Disease

Volumn 4, Issue 6, 2013, Pages

  Xiaoping, L ^a,b,c,d,e   Zhibin, Y ^a,b,c,d   Wenjuan, L ^a,b,c   Zeyou, W ^a,b,c,d   Gang, X ^a,b,c,d   Zhaohui, L ^a,b,c   Ying, Z ^a,b,c   Minghua, W ^a,b,c,d   Guiyuan, L ^a,b,c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c BEIJING HOSPITAL   (China)

^d The Center for Skull Base Surgery and Neurooncology   (China)

^e GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

Author keywords

CPEB1; histone modifition; hypomethylation; miR 101; p53; senescence

Indexed keywords

CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN; CYTOPLASMIC POLYADENYLATION ELEMENT BINDING PROTEIN 1; EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; HISTONE H3; HISTONE H4; MESSENGER RNA; MICRORNA 101; PROTEIN P53; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CARCINOGENESIS; CELL AGING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN LOCALIZATION; REGULATOR GENE; RNA TRANSLATION;

EID: 84879673926     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.197     Document Type: Article

References (52)

1. Starkweather AR, Sherwood P, Lyon DE, McCain NL, Bovbjerg DH, Broaddus WC. A biobehavioral perspective on depressive symptoms in patients with cerebral astrocytoma. J Neurosci Nurs 2011; 43: 17-28.
2. Winkler F, Kienast Y, Fuhrmann M, Von Baumgarten L, Burgold S, Mitteregger G et al. Imaging glioma cell invasion in vivo reveals mechanisms of dissemination and peritumoral angiogenesis. Glia 2009; 57: 1306-1315.
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72: 141-196.
4. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61: 3225-3229.
5. Horiguchi K, Tomizawa Y, Tosaka M, Ishiuchi S, Kurihara H, Mori M et al. Epigenetic inactivation of RASSF1A candidate tumor suppressor gene at 3p21.3 in brain tumors. Oncogene 2003; 22: 7862-7865.
6. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y et al. p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 2001; 11: 159-168.
7. Waha A, Guntner S, Huang TH, Yan PS, Arslan B, Pietsch T et al. Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia 2005; 7: 193-199.
8. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N et al. Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 2011; 6: e26740.
9. Rajendran G, Shanmuganandam K, Bendre A, Muzumdar D, Goel A, Shiras A. Epigenetic regulation of DNA methyltransferases: DNMT1 and DNMT3B in gliomas. J Neurooncol 2011; 104: 483-494.
10. Liu X, Tang H, Wang Z, Huang C, Zhang Z, She X et al. F10 gene hypomethylation, a putative biomarker for glioma prognosis. J Neurooncol 2012; 107: 479-485.
11. Liu X, Tang H, Zhang Z, Li W, Wang Z, Zheng Y et al. POTEH hypomethylation, a new epigenetic biomarker for glioma prognosis. Brain Res 2011; 1391: 125-131.
12. Groisman I, Jung MY, Sarkissian M, Cao Q, Richter JD. Translational control of the embryonic cell cycle. Cell 2002; 109: 473-483.
13. Novoa I, Gallego J, Ferreira PG, Mendez R. Mitotic cell-cycle progression is regulated by CPEB1 and CPEB4-dependent translational control. Nat Cell Biol 2010; 12: 447-456.
14. Groisman I, Ivshina M, Marin V, Kennedy NJ, Davis RJ, Richter JD. Control of cellular senescence by CPEB. Genes Dev 2006; 20: 2701-2712.
15. Sasayama T, Marumoto T, Kunitoku N, Zhang D, Tamaki N, Kohmura E et al. Overexpression of Aurora-A targets cytoplasmic polyadenylation element binding protein and promotes mRNA polyadenylation of Cdk1 and cyclin B1. Genes Cells 2005; 10: 627-638.
16. Braig M, Schmitt CA. Oncogene-induced senescence: putting the brakes on tumor development. Cancer Res 2006; 66: 2881-2884.
17. Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer 2011; 10: 124.
18. Burns DM, D'Ambrogio A, Nottrott S, Richter JD. CPEB and two poly(A) polymerases control miR-122 stability and p53 mRNA translation. Nature 2011; 473: 105-108.
19. Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci USA 1995; 92: 9363-9367.
20. Lee BY, Han JA, Im JS, Morrone A, Johung K, Goodwin EC et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell 2006; 5: 187-195.
21. Saito Y, Suzuki H, Matsuura M, Sato A, Kasai Y, Yamada K et al. MicroRNAs in Hepatobiliary and Pancreatic Cancers. Front Genet 2012; 2: 66.
22. Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 2008; 322: 1695-1699.
23. Chiang CW, Huang Y, Leong KW, Chen LC, Chen HC, Chen SJ et al. PKCalpha mediated induction of miR-101 in human hepatoma HepG2 cells. J Biomed Sci 2010; 17: 35.
24. Sessa L, Breiling A, Lavorgna G, Silvestri L, Casari G, Orlando V et al. Synthesis and loss of Polycomb group repression accompanies the colinear activation of the human HOXA cluster. RNA 2007; 13: 223-239.
25. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-1080.
26. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 2009; 15: 3927-3937.
27. Hong GM, Bain LJ. Sodium arsenite represses the expression of myogenin in C2C12 mouse myoblast cells through histone modifications and altered expression of Ezh2, Glp, and Igf-1. Toxicol Appl Pharmacol 2012; 260: 250-259.
28. Shumaker DK, Dechat T, Kohlmaier A, Adam SA, Bozovsky MR, Erdos MR et al. Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci USA 2006; 103: 8703-8708.
29. Murata T, Kondo Y, Sugimoto A, Kawashima D, Saito S, Isomura H et al. Epigenetic histone modification of Epstein-Barr virus BZLF1 promoter during latency and reactivation in Raji cells. J Virol 2012; 86: 4752-4761.
30. Patterson E, Webb R, Weisbrod A, Bian B, He M, Zhang L et al. The microRNA expression changes associated with malignancy and SDHB mutation in pheochromocytoma. Endocr Relat Cancer 2012; 19: 157-166.
31. Luo L, Zhang T, Liu H, Lv T, Yuan D, Yao Y et al. MiR-101 and Mcl-1 in non-small-cell lung cancer: expression profile and clinical significance. Med Oncol 2012; 29: 1681-1686.
32. Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, Stankova L, Shahin NA, LaFleur BJ et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther 2012; 13: 175-183.
33. Carvalho J, van Grieken NC, Pereira PM, Sousa S, Tijssen M, Buffart TE et al. Lack of microRNA-101 causes E-cadherin functional deregulation through EZH2 up-regulation in intestinal gastric cancer. J Pathol 2012; 228: 31-44.
34. Semaan A, Qazi AM, Seward S, Chamala S, Bryant CS, Kumar S et al. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)). Pharm Res 2011; 28: 3079-3090.
35. Su H, Yang JR, Xu T, Huang J, Xu L, Yuan Y et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009; 69: 1135-1142.
36. Pang Y, Young CY, Yuan H. MicroRNAs and prostate cancer. Acta Biochim Biophys Sin 2010; 42: 363-369.
37. Wang HJ, Ruan HJ, He XJ, Ma YY, Jiang XT, Xia YJ et al. MicroRNA-101 is downregulated in gastric cancer and involved in cell migration and invasion. Eur J Cancer 2010; 46: 2295-2303.
38. Jones KJ, Korb E, Kundel MA, Kochanek AR, Kabraji S, McEvoy M et al. CPEB1 regulates beta-catenin mRNA translation and cell migration in astrocytes. Glia 2008; 56: 1401-1413.
39. Yue X, Wang P, Xu J, Zhu Y, Sun G, Pang Q et al. MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncol Rep 2012; 27: 1200-1206.
40. Tang H, Liu X, Wang Z, She X, Zeng X, Deng M et al. Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth. Brain Res 2011; 1390: 21-32.
41. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 2006; 6: 846-856.
42. Otte AP, Kwaks TH. Gene repression by Polycomb group protein complexes: a distinct complex for every occasion? Curr Opin Genet Dev 2003; 13: 448-454.
43. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002; 16: 2893-2905.
44. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007; 39: 232-236.
45. Au SL, Wong CC, Lee JM, Fan DN, Tsang FH, Ng IO et al. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. Hepatology 2012; 56: 622-631.
46. Hashimoto H, Vertino PM, Cheng X. Molecular coupling of DNA methylation and histone methylation. Epigenomics 2011; 2: 657-669.
47. Rinn JL, Kertesz M, Wang JK, Squazzo SL, Xu X, Brugmann SA et al. Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs. Cell 2007; 129: 1311-1323.
48. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007; 6: 1403-1412.
49. Lehnertz B, Ueda Y, Derijck AA, Braunschweig U, Perez-Burgos L, Kubicek S et al. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr Biol 2003; 13: 1192-1200.
50. Tachibana M, Ueda J, Fukuda M, Takeda N, Ohta T, Iwanari H et al. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev 2005; 19: 815-826.
51. Gonzalo S, Garcia-Cao M, Fraga MF, Schotta G, Peters AH, Cotter SE et al. Role of the RB1 family in stabilizing histone methylation at constitutive heterochromatin. Nat Cell Biol 2005; 7: 420-428.
52. Sharma G, Mirza S, Parshad R, Srivastava A, Datta Gupta S, Pandya P et al. CpG hypomethylation of MDR1 gene in tumor and serum of invasive ductal breast carcinoma patients. Clin Biochem 2010; 43: 373-379.